Oxford Cancer Analytics – a medical technology company developing blood tests for early cancer detection using advanced proteomics and AI – announced it has raised $11 million in Series A funding from global investors, such as in-field institutional investors in disease detection and diagnostics.
This funding round was led by We Venture Capital and Cross-Border Impact Ventures with participation from return investors Eka Ventures and Civilization Ventures, and new investors DigitalDx Ventures, Macmillan Cancer Support (Innovation Impact Investment Portfolio), Aurelium Ventures, OKG Capital, and prominent angel investors. And this investment positions the company to develop and globally commercialize its new generation of minimally invasive liquid biopsy blood tests for the early detection of lung cancer.
OXcan also appointed Dr. Heinrich Roder as Senior Vice President of Research & Development. With over two decades of experience in lung cancer liquid biopsy and commercialization, Dr. Roder will further advance OXcan’s lung cancer blood test for deployment.
OXcan’s protein-based blood test identifies molecular signatures for high-risk lung cancer patients, utilizing a diverse global biobank to ensure worldwide scalability. And using advanced proteomics and AI, it fills an unmet niche in the liquid biopsy space by offering a protein-based blood test with high accuracy to detect cancers with the highest mortality burden.
Since 2023, OXcan formed global partnerships, collaborating with over 20 healthcare centers across three continents to develop and deploy its technology.
